A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients

January 22, 2021 | Hospital-Based | 

2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.

Be the First to Know

Sign up to get updates when we add new off-label treatments, articles, videos, and clinical trials!